Spironolactone After Liver Transplant

Wake Forest University (WFU)

Status and phase: Completed; Phase 4

Conditions: Transplant, Liver

Treatments: Drug: Spironolactone

Study type: Interventional

Funder types: Other

Identifiers

NCT02883400

12-14-03A

Details and patient eligibility

About

To study spironolactone to prevent calcineurin inhibitor (CNI) kidney injury.

Full description

The aim of this study is to determine if spironolactone decreases nephrotoxicity from calcineurin inhibitors in liver transplant recipients and to determine the best study of renal function in liver transplant recipients.

Enrollment: 30 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• liver transplant

Exclusion criteria

• dual organ transplant

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

30 participants in 2 patient groups

SOC-Standard of care

No Intervention group

Description:

standard of care, nontreatment

spironolactone

Experimental group

Description:

spironolactone

Treatment:

Drug: Spironolactone